This Article Figures Only Full Text Full Text (PDF) View CVN Interview Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fernandes, V. L. Articles by Spencer, W. H. Search for Related Content PubMed Articles by Fernandes, V. L. Articles by Spencer, W. H., III

Follow-Up of Alcohol Septal Ablation for Symptomatic Hypertrophic Obstructive Cardiomyopathy

The Baylor and Medical University of South Carolina Experience 1996 to 2007

Valerian L. Fernandes, MD^_*, Christopher Nielsen, MD^_*, Sherif F. Nagueh, MD, Amy E. Herrin, MS, Christine Slifka, RN^_*, Jennifer Franklin, RN, William H. Spencer, III, MD^_*,_*

^_* Division of Cardiology, Medical University of South Carolina, Charleston, South Carolina
Division of Cardiology, Methodist-DeBakey Heart Center, Houston, Texas
Department of Biostatistics, Bioinformatics and Epidemiology, Medical University of South Carolina, Charleston, South Carolina

^_* Reprint requests and correspondence: Dr. William H. Spencer, III, Department of Medicine, Division of Cardiology, Medical University of South Carolina, 25 Courtenay Drive, ART 7031, Charleston, South Carolina 29425 (Email: spencerw{at}musc.edu).

Objectives: This study sought to determine the long-term outcome of alcohol septal ablation (ASA).

Background: There are inadequate data on the long-term outcome of ASA for symptomatic hypertrophic obstructive cardiomyopathy (HOCM).

Methods: Six hundred and twenty-nine patients were enrolled consecutively (1996 to 2007) and 98.4% (n = 619) underwent ASA with 92% follow-up in 2007. Evaluation included deaths, procedural complications, pacemaker requirement, repeat ASA, and myectomy/valve surgery. Follow-up parameters included angina (Canadian Cardiovascular Society score), dyspnea (New York Heart Association functional class), exercise time, and echocardiographic indices (septal thickness, ejection fraction, resting and provoked gradients).

Results: Ethanol (2.6 ± 1.0 ml) was injected into 1.3 ± 0.5 septal arteries, inducing a septal infarct. Complications included death 1% (n = 6), permanent pacemaker requirement 8.2% (n = 52), coronary dissection 1.3% (n = 8), and worsening mitral regurgitation 0.3% (n = 2). The mean follow-up was 4.6 ± 2.5 years (range: 3 months to 10.2 years). During follow-up, New York Heart Association functional class decreased from 2.8 ± 0.6 to 1.2 ± 0.5 (p < 0.001); Canadian Cardiovascular Society angina score decreased from 2.1 ± 0.9 to 1.0 ± 0 (p < 0.001); and exercise time increased from 4.8 ± 3.3 to 8.2 ± 1.0 (p < 0.001) min. The resting and provoked left ventricular outflow tract gradients decreased progressively (p < 0.001) and remained low during follow-up. The septal thickness decreased from 2.1 ± 0.5 cm to 1.0 ± 0.1 cm (p < 0.001) and the ejection fraction decreased from 68 ± 9% to 62 ± 3% (p < 0.001). The survival estimates at 1, 5, and 8 years were 97%, 92%, and 89%, respectively.

Conclusions: The initial benefits of ASA were maintained during follow-up.

Key Words: alcohol • cardiomyopathy • hypertrophy

Abbreviations and Acronyms   ASA = alcohol septal ablation   AV = atrioventricular   CCS = Canadian Cardiovascular Society   CI = confidence interval   HOCM = hypertrophic obstructive cardiomyopathy   ICD = implantable cardioverter-defibrillator   LVOT = left ventricular outflow tract   NYHA = New York Heart Association

This article has been cited by other articles:

				B. J. Gersh, B. J. Maron, R. O. Bonow, J. A. Dearani, M. A. Fifer, M. S. Link, S. S. Naidu, R. A. Nishimura, S. R. Ommen, H. Rakowski, et al. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons J. Am. Coll. Cardiol., December 13, 2011; 58(25): e212 - e260. [Full Text] [PDF]

				S. F. Nagueh, B. M. Groves, L. Schwartz, K. M. Smith, A. Wang, R. G. Bach, C. Nielsen, F. Leya, J. M. Buergler, S. K. Rowe, et al. Alcohol Septal Ablation for the Treatment of Hypertrophic Obstructive Cardiomyopathy: A Multicenter North American Registry J. Am. Coll. Cardiol., November 22, 2011; 58(22): 2322 - 2328. [Abstract] [Full Text] [PDF]

				M. A. Fifer and U. Sigwart Hypertrophic obstructive cardiomyopathy: alcohol septal ablation Eur. Heart J., May 1, 2011; 32(9): 1059 - 1064. [Abstract] [Full Text] [PDF]

				T. Lawrenz, B. Borchert, C. Leuner, M. Bartelsmeier, J. Reinhardt, C. Strunk-Mueller, D. Meyer Zu Vilsendorf, M. Schloesser, G. Beer, F. Lieder, et al. Endocardial Radiofrequency Ablation for Hypertrophic Obstructive Cardiomyopathy: Acute Results and 6 Months' Follow-Up in 19 Patients J. Am. Coll. Cardiol., February 1, 2011; 57(5): 572 - 576. [Abstract] [Full Text] [PDF]

				S. R. Dixon, C. L. Grines, and W. W. O'Neill The Year in Interventional Cardiology J. Am. Coll. Cardiol., June 2, 2009; 53(22): 2080 - 2097. [Full Text] [PDF]